Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Estrella Immunopharma Inc (ESLA)

Estrella Immunopharma Inc (ESLA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 75,154
  • Shares Outstanding, K 37,766
  • Annual Sales, $ 0 K
  • Annual Income, $ -7,312 K
  • EBIT $ -12 M
  • EBITDA $ -12 M
  • 60-Month Beta 0.53
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr N/A
See More
  • Average Estimate N/A
  • Number of Estimates N/A
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.5000 +32.67%
on 11/21/25
3.0100 -33.89%
on 11/07/25
-0.5700 (-22.27%)
since 11/05/25
3-Month
0.9901 +100.99%
on 09/10/25
3.1500 -36.83%
on 11/04/25
+0.9400 (+89.52%)
since 09/05/25
52-Week
0.7301 +172.57%
on 04/01/25
3.1500 -36.83%
on 11/04/25
+0.7700 (+63.11%)
since 12/05/24

Most Recent Stories

More News
Estrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB Recommendation

An independent Data Safety Monitoring Board (DSMB) confirms EB103’s favorable safety profile with no treatment-related serious adverse events (SAEs) even in high-risk patients who are ineligible for...

ESLA : 1.9900 (+3.11%)
Top 100 Stocks to Buy: Two Penny Stocks Moved Up 51 Spots. Should You Buy Either?

Royalty Management Holding Corp. and Estrella Immunopharma had the most significant moves on Monday on Barchart’s Top 100 Stocks to Buy, moving up 51 spots. Should you buy either penny stock? If you’re...

RMCO : 2.32 (-7.94%)
AREC : 3.00 (-5.36%)
ESLA : 1.9900 (+3.11%)
Estrella Immunopharma Completes Second Dose Cohort in STARLIGHT-1 Trial of EB103 with Complete Responses in All Evaluable Patients

Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS ® ...

ESLA : 1.9900 (+3.11%)
Why Armata Pharmaceuticals Skyrocketed 370% Today

Armata Pharmaceuticals (NYSE American: ARMP) surprised Wall Street on Wednesday after its stock rocketed as much as 370% intraday on the back of groundbreaking mid-stage clinical results for its bacteriophage-based...

ESLA : 1.9900 (+3.11%)
SLP : 19.64 (-4.15%)
ARMP : 5.63 (-5.22%)
BNBX : 3.00 (-3.23%)
IBIO : 1.2000 (-6.25%)
Estrella Immunopharma Regains Compliance with Nasdaq Listing Requirements

Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS ® ...

ESLA : 1.9900 (+3.11%)
Top 5 Biotech Stocks That Saw Biggest Retail Following Jump Last Week

Investors on Stocktwits flocked to these five biotech stocks last week, ending Feb. 21, 2025, driven by buyout buzz, bullish analyst calls, and promising clinical developments.

SLDB : 5.77 (-2.53%)
SLRN : 2.27 (+1.79%)
ESLA : 1.9900 (+3.11%)
CADL : 5.33 (+1.33%)
ADTX : 3.08 (+5.84%)

Business Summary

Estrella Immunopharma Inc is a preclinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS(R) T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. The company's lead product candidate includes EB103 and EB104. Estrella...

See More

Key Turning Points

3rd Resistance Point 2.3957
2nd Resistance Point 2.2745
1st Resistance Point 2.1323
Last Price 1.9900
1st Support Level 1.8689
2nd Support Level 1.7477
3rd Support Level 1.6055

See More

52-Week High 3.1500
Fibonacci 61.8% 2.2256
Last Price 1.9900
Fibonacci 50% 1.9401
Fibonacci 38.2% 1.6545
52-Week Low 0.7301

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar